Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated at StockNews.com


Analysts at StockNews.com began coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE – Get Rating) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the stock.

Ampio Pharmaceuticals Trading Down 5.2 %

Shares of AMPE opened at $0.11 on Friday. The firm’s 50-day simple moving average is $0.17. The company has a market cap of $24.71 million, a P/E ratio of -0.99 and a beta of 1.65. Ampio Pharmaceuticals has a 12-month low of $0.10 and a 12-month high of $1.83.

Ampio Pharmaceuticals (NYSE:AMPE – Get Rating) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). On average, equities research analysts expect that Ampio Pharmaceuticals will post -0.08 EPS for the current year.

Ampio Pharmaceuticals Company Profile

(Get Rating)

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19.

See also



Receive News & Ratings for Ampio Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Reply

Your email address will not be published.

Back to top button
DRAGONINKHOUSE